Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC

The Quick Take
TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Local
Finance of America grows origination volume but reports $110M loss in Q3
Funded volume increased 24% year over year to $748 million, but higher interest rates pressured origination margins
Business
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
37 Saudi tourism partners connect with international travel buyers to showcase new destinations, experiences and opportunities for winter and beyond. Saudi…
Business
The ALS Association Secures Major Legislative Victory with ACT for ALS Becoming Law
President signs the bipartisan measure, extending life-saving research and treatment access programs through 2031 ARLINGTON, Va., Nov. 3, 2026 /PRNewswire/ --…
Business
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China…
